<DOC>
	<DOCNO>NCT00448552</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give oxaliplatin together capecitabine work treat patient relapse metastatic head neck cancer .</brief_summary>
	<brief_title>Oxaliplatin Capecitabine Treating Patients With Relapsed Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient chemotherapy naïve relapse metastatic head neck cancer treat oxaliplatin capecitabine . Secondary - Evaluate safety toxicity regimen patient . - Determine one-year survival overall survival patient . OUTLINE : Patients receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 2-15 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm head neck cancer Relapsed metastatic disease Measurable disease No CNS metastases ( unless CNS metastases stable &gt; 3 month ) No clinically significant pericardial effusion PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Absolute granulocyte count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Bilirubin &lt; 2.0 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Alkaline phosphatase &lt; 2.5 time ULN ( 5 time ULN liver metastases present 10 time ULN bone disease present ) Creatinine clearance ≥ 30 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day completion study treatment No clinically serious , uncontrolled cardiovascular disease No New York Heart Association class IIIIV heart disease No myocardial infarction within past 6 month No congestive heart failure No unstable angina No arrhythmia No concurrent serious , uncontrolled infection No cancer require treatment within past 5 year , except cure nonmelanoma skin cancer treat situ cervical cancer No loss physical integrity upper gastrointestinal tract malabsorption syndrome No history persistent neurosensory disorder include , limited , peripheral neuropathy No history uncontrolled seizure CNS disorder No history psychiatric disability serious uncontrolled medical condition would preclude study compliance No history clinically significant interstitial lung disease and/or pulmonary fibrosis No prior hypersensitivity unanticipated severe reaction fluoropyrimidine therapy , fluorouracil , platinumbased compound PRIOR CONCURRENT THERAPY : No prior chemotherapy metastatic relapse disease More 4 week since prior major surgery recover More 4 week since prior participation investigational drug study At least 6 month since prior adjuvant fluoropyrimidine therapy No prior fluoropyrimidines At least 6 month since prior adjuvant platinumbased therapy No prior platinumbased therapy No concurrent radiotherapy head neck No concurrent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
</DOC>